We work to identify patient needs and develop ideal product solutions tailored to address those needs.
Our first commercial product is ZECUITY® sumatriptan iontophoretic transdermal system (patch) for the acute treatment of migraine. We are seeking commercialization partners in the U.S. and worldwide.
In addition, we have a strong pipeline based on our biodegradable implant technology that allows us to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson’s disease, utilizes a leading FDA-approved dopamine agonist and is being developed to provide up to two months of continuous delivery. NP202 is being developed to address patient noncompliance, a long-standing problem in the treatment of schizophrenia and bipolar disorder, by providing three months of continuous delivery of risperidone, an atypical antipsychotic. We are seeking a development partner for each of these candidates to capitalize on their commercial potential worldwide.
Beyond our current product pipeline, we intend to be a leader in the rapidly growing transdermal patch market with our active SmartRelief technology, delivering innovative solutions across a range of therapeutic areas.